CagriSema · Amylin + GLP-1 Dual Combination
Pre-mixed research blend of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Studied in dual-mechanism metabolic pathway models.
CagriSema is a fixed-ratio combination of cagrilintide (long-acting amylin receptor agonist) and semaglutide (GLP-1 receptor agonist). Research interest centers on complementary satiety and glycemic mechanisms. Phase 3 REDEFINE trials have shown ~22% body weight reduction data in clinical research.
Store lyophilized at -20°C. Reconstitute with bacteriostatic water. Stable 28 days at 2–8°C post-reconstitution.